Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Published:2024-06 Issue:10445 Volume:403 Page:2709-2719
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Gelderblom Hans,Bhadri Vivek,Stacchiotti Silvia,Bauer Sebastian,Wagner Andrew J,van de Sande Michiel,Bernthal Nicholas M,López Pousa Antonio,Razak Albiruni Abdul,Italiano Antoine,Ahmed Mahbubl,Le Cesne Axel,Tinoco Gabriel,Boye Kjetil,Martín-Broto Javier,Palmerini Emanuela,Tafuto Salvatore,Pratap Sarah,Powers Benjamin C,Reichardt Peter,Casado Herráez Antonio,Rutkowski Piotr,Tait Christopher,Zarins Fiona,Harrow Brooke,Sharma Maitreyi G,Ruiz-Soto Rodrigo,Sherman Matthew L,Blay Jean-Yves,Tap William D,Loong Herbert,Brunello Antonella,Krieg Andreas,Algulnik Mark,Riedel Richard,Okuno Scott,Loggers Elizabeth,Alcindor Thierry,Ferraresi Virginia,Serrano César,Randall R. Lor,Wilky Breelyn,Ravi Vinod

Funder

Deciphera Pharmaceuticals LLC

Publisher

Elsevier BV

Reference30 articles.

1. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts;Stacchiotti;Cancer Treat Rev,2023

2. Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages;Smith;Mol Cancer Ther,2021

3. Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT;Tap;Clin Cancer Res,2022

4. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy;Cannarile;J Immunother Cancer,2017

5. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells;West;Proc Natl Acad Sci USA,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib;Clinical Cancer Research;2024-07-12

2. Vimseltinib improves outcomes in tenosynovial giant cell tumour;Nature Reviews Clinical Oncology;2024-06-24

3. Vimseltinib for tenosynovial giant cell tumour;The Lancet;2024-06